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This study deals with the analysis of the factors as-
sociated with drug utilization and is therefore a phar-
macoepidemiology study and, specifically, a drug utili-
zation study (DUS)1.
Although abundant literature on the subject has been
published, each new study in this field contributes com-
plementary information, specific to the population stu-
died, since a large proportion of the factors determining
drug utilization are sociodemographic; consequently,
these studies generally have little external validity.
In the present study, the patients were recruited from
health centers and their characteristics, as well as data
on drug utilization, were gathered through a question-
naire. Although constructing a primary database can con-
fer researchers with greater freedom and allow the va-
riables gathered specifically for the study to be studied,
the potential of secondary sources such as the Natio-
nal Health Survey or the Pharmaceutical Billing Data-
base2, the latter in combination with the Health Identi-
fication Card, should not be underestimated. In addition
to efficiency, both databases are representative of the
population in a way that is difficult to achieve in data-
bases generated specifically for a particular study.
However, secondary databases also present major
limitations. Pharmaceutical Billing Databases, for exam-
ple, do not contain information on the indication moti-
vating the drug prescription, making studies of indica-
tion-prescription and prescription-indication impossible2.
And these are, in our opinion, precisely the designs cu-
rrently required in DUS in Spain.
The Database for Pharmacoepidemiological Rese-
arch in Primary Care1 of the Spanish Medication
Agency, which includes the participation of 10 autono-
mous communities and approximately 1,000 physicians,
integrates data on signs and symptoms, diagnosis, in-
dication and prescription, in addition to patient charac-
teristics. In the next few years, this database will allow
major advances to be made in the DUS performed in
primary care.
Importantly, the efficacy of this database will be de-
termined by its accessibility to the distinct research
groups. The Spanish Medication Agency should approve
the conditions for its use by researchers as soon as pos-
sible.
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